HUMAN NEUROPEPTIDE-Y Y(1)-RECEPTOR ANTISENSE OLIGODEOXYNUCLEOTIDE SPECIFICALLY INHIBITS NEUROPEPTIDE Y-EVOKED VASOCONSTRICTION

被引:29
|
作者
ERLINGE, D
EDVINSSON, L
BRUNKWALL, J
YEE, F
WAHLESTEDT, C
机构
[1] LUND UNIV,DEPT INTERNAL MED,S-22101 LUND,SWEDEN
[2] LUND UNIV,DEPT EXPTL RES,S-22101 LUND,SWEDEN
[3] CORNELL UNIV,MED CTR,COLL MED,DEPT NEUROL & NEUROSCI,DIV NEUROBIOL,NEW YORK,NY 10021
[4] LUND UNIV,MALMO GEN HOSP,DEPT SURG,S-22101 LUND,SWEDEN
关键词
NEUROPEPTIDE-Y; BLOOD VESSEL (HUMAN); ANTISENSE; NEUROPEPTIDE-Y Y(1)-RECEPTOR;
D O I
10.1016/0014-2999(93)90548-V
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This paper describes a new approach for the development of an inhibitor of the contractile responses of neuropeptide Y in human blood vessels by the use of an antisense oligodeoxynucleotide complementary to human neuropeptide Y Y1 receptor mRNA. One micromolar of an antisense 18-base oligodeoxynucleotide (hY1-AS), corresponding to the human Y1 receptor NH2-terminus, was incubated with segments of human subcutaneous arteries and veins for 48 h at 37-degrees-C. Control vessels were incubated with the corresponding sense oligodeoxynucleotide (hY1-S) or a 3-base mismatched antisense oligodeoxynucleotide (hY1-MM) or no oligodeoxynucleotide. The contractile response to neuropeptide Y was markedly attenuated in both arteries and veins after treatment with hY1-AS, but was unaffected by hY1-S or hY1-MM. The pD2 values, i.e. the potency of neuropeptide Y, did not differ in hY1-AS treated vessels, suggesting a non-competitive receptor interaction as a result of down-regulation of Y1 receptors. Responses to noradrenaline or high K+ were unaffected by hY1-AS. This study may represent a new and highly specific approach to vascular pharmacology.
引用
收藏
页码:77 / 80
页数:4
相关论文
共 50 条
  • [41] NEUROPEPTIDE-Y AND CARDIOVASCULAR REGULATION
    MCCLOSKEY, DI
    POTTER, EK
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1991, 18 (01) : 47 - 49
  • [42] NEUROPEPTIDE-Y AS AN AUTONOMIC NEUROTRANSMITTER
    POTTER, EK
    PHARMACOLOGY & THERAPEUTICS, 1988, 37 (02) : 251 - 273
  • [43] NEUROPEPTIDE-Y IN PHEOCHROMOCYTOMAS AND GANGLIONEUROBLASTOMAS
    ADRIAN, TE
    ALLEN, JM
    TERENGHI, G
    BACARESEHAMILTON, AJ
    BROWN, MJ
    POLAK, JM
    BLOOM, SR
    LANCET, 1983, 2 (8349): : 540 - 542
  • [44] NEUROPEPTIDE-Y AND NEUROENDOCRINE TUMORS
    COMOY, E
    LEGAC, E
    GROUZMANN, E
    BOHUON, C
    ANNALES DE BIOLOGIE CLINIQUE, 1988, 46 (07) : 563 - 563
  • [45] SOLUTION SYNTHESIS OF HUMAN NEUROPEPTIDE-Y (HNPY)
    ONO, S
    KITAGAWA, K
    FUTAKI, S
    KIYAMA, S
    OOI, Y
    AKITA, T
    HIGASHIDE, S
    INOUE, K
    SUMI, S
    TOBE, T
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1989, 37 (07) : 1925 - 1929
  • [46] HUMAN PLACENTA AS A SOURCE AND TARGET OF NEUROPEPTIDE-Y
    PETRAGLIA, F
    COUKOS, G
    GIARDINO, L
    CALZA, L
    DERAMUNDO, BM
    COMITINI, G
    SEGRE, A
    GENAZZANI, AR
    RECENT ADVANCES IN BASIC AND CLINICAL NEUROENDOCRINOLOGY, 1989, 864 : 45 - 52
  • [47] THE EFFECTS OF NEUROPEPTIDE-Y ON THE CIRCULATION
    EDVINSSON, L
    ISI ATLAS OF SCIENCE-PHARMACOLOGY, 1988, 2 (04): : 357 - 361
  • [48] MICROCIRCULATORY DYNAMICS OF NEUROPEPTIDE-Y
    KIM, DY
    DURAN, WR
    KOBAYASHI, I
    DANIELS, AJ
    DURAN, WN
    MICROVASCULAR RESEARCH, 1994, 48 (01) : 124 - 134
  • [49] NEUROPEPTIDE-Y AND SYMPATHETIC NEUROTRANSMISSION
    LUNDBERG, JM
    FRANCOCERECEDA, A
    LACROIX, JS
    PERNOW, J
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 611 : 166 - 174
  • [50] BENEXTRAMINE NEUROPEPTIDE-Y RECEPTOR INTERACTIONS - CONTRIBUTION OF THE BENZYLIC MOIETIES TO [H-3] NEUROPEPTIDE-Y DISPLACEMENT ACTIVITY
    DOUGHTY, MB
    CHAURASIA, CS
    LI, K
    JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (02) : 272 - 279